In a clinical setting, CPPs can be formulated for topical administration to enhance the ocular absorption of age-related macular degeneration (AMD) therapies, such as protein-based therapies (e.g., anti-vascular endothelial growth factor agents) and small peptide therapies (e.g., the novel therapeutic candidate Apolipoprotein A-I mimetic peptide 4F, ApoAI) [2,3]. The gene discussed is VEGFA; the disease is age-related macular degeneration.